ADVERTISEMENT
Considerations for Managing Patients With HER2-Positive Breast Cancer
In this expert roundtable series, 3 leading breast cancer specialists discuss the management of patients with HER2-positive breast cancer. The 4-part discussion series is led by Reshma Mahtani, DO, Miami Cancer Institute, Florida, who is joined by Terry Mamounas, MD, Orlando Health Cancer Institute, Florida, and Jane Meisel, MD, Winship Cancer Institute, Atlanta, Georgia.
Part 1:
Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer
In this video, our experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology perspectives.
Part 2:
Managing Patients With Stage 1 HER2-Positive Breast Cancer
In this video, our experts discuss the management of patients with stage 1, HER2-positive tumors, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.
Part 3:
Optimizing Treatment for Patients With High-Risk HER2-Positive Breast Cancer
In this video, our experts share insights on optimizing therapy for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the KATHERINE trial.
Part 4:
Pertuzumab Plus Trastuzumab for Early-Stage HER2-Positive Breast Cancer
In the final installment of this discussion series, our experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
